ID | 65166 |
FullText URL | |
Author |
Umakoshi, Noriyuki
Department of Radiology, Okayama University Hospital
Iguchi, Toshihiro
Deptartment of Radiological Technology, Okayama University Graduate School of Health Science
Kaken ID
Matsui, Yusuke
Department of Radiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Tomita, Koji
Department of Radiology, Okayama University Hospital
Uka, Mayu
Department of Radiology, Okayama University Hospital
Kawabata, Takahiro
Department of Radiology, Okayama University Hospital
Munetomo, Kazuaki
Department of Radiology, Okayama University Hospital
Nagata, Shoma
Department of Radiology, Okayama University Hospital
Gobara, Hideo
Division of Medical Informatics, Okayama University Hospital
Araki, Motoo
Department of Urology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
ORCID
Kaken ID
publons
researchmap
Hiraki, Takao
Department of Radiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Kaken ID
publons
researchmap
|
Abstract | Purpose To retrospectively evaluate cryoablation combined with prior transcatheter arterial embolization (TAE) for renal cell carcinoma (RCC) in non-dialysis patients with stage 4 or 5 chronic kidney disease (CKD).
Materials and methods Patients with stage 4 or 5 CKD undergoing TAE and cryoablation for RCC between May 2012 and October 2021 were included. TAE was selectively performed using iodized oil with absolute ethanol or gelatin sponge 1–14 days before cryoablation. Local efficacy, safety, and changes in renal function were evaluated. Results Nine patients (seven men and two women; median age, 64 years; range 52–88 years) with nine RCCs (mean diameter, 3.0 ± 1.0 cm; range 1.7–4.7 cm) were included. The mean pre-treatment estimated glomerular filtration rate (eGFR) was 24.2 ± 5.6 ml/min/1.73 m2 (range 10.4–29.2 ml/min/1.73 m2). The mean amount of contrast medium used in TAE was 58 ± 29 ml (range 40–128 ml). Except in one patient (grade 3 pyelonephritis), no grade ≥ 3 complications occurred. During the follow-up period (median, 18 months; range 7–54 months), no local tumor progression occurred. In two patients with pre-treatment eGFR of < 20 ml/min/1.73 m2, hemodialysis was initiated at 3 and 19 months after cryoablation. At their last follow-up, the remaining seven patients showed a decrease of 6.2 ± 5.3 ml/min/1.73 m2 (range 0.7–17.2 ml/min/1.73 m2) in their eGFR. Conclusion Cryoablation combined with TAE for RCC in non-dialysis patients with stage 4 or 5 CKD was effective and safe, with an acceptable impact on renal function. |
Keywords | Renal cryoablation
Transcatheter arterial embolization
Chronic kidney disease
|
Note | The version of record of this article, first published in Japanese Journal of Radiology, is available online at Publisher’s website: http://dx.doi.org/10.1007/s11604-023-01416-z
|
Published Date | 2023-04-01
|
Publication Title |
Japanese Journal of Radiology
|
Publisher | Springer Science and Business Media LLC
|
ISSN | 1867-1071
|
Content Type |
Journal Article
|
language |
English
|
OAI-PMH Set |
岡山大学
|
Copyright Holders | © The Author(s) 2023
|
File Version | publisher
|
PubMed ID | |
DOI | |
Web of Science KeyUT | |
Related Url | isVersionOf https://doi.org/10.1007/s11604-023-01416-z
|
License | http://creativecommons.org/licenses/by/4.0/
|
Citation | Umakoshi, N., Iguchi, T., Matsui, Y. et al. Renal cryoablation combined with prior transcatheter arterial embolization in non-dialysis patients with stage 4 or 5 chronic kidney disease: a retrospective study. Jpn J Radiol (2023). https://doi.org/10.1007/s11604-023-01416-z
|